Re: Cabergoline versus levodopa monotherapy: A decision analysis
Identifieur interne : 003B68 ( Main/Exploration ); précédent : 003B67; suivant : 003B69Re: Cabergoline versus levodopa monotherapy: A decision analysis
Auteurs : Connie Marras [Canada]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-06.
English descriptors
- KwdEn :
- Age Factors, Antiparkinson Agents (economics), Antiparkinson Agents (therapeutic use), Cost-Benefit Analysis, Decision Support Techniques, Ergolines (economics), Ergolines (therapeutic use), Humans, Levodopa (economics), Levodopa (therapeutic use), Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (economics), Prospective Studies, Questionnaires.
- MESH :
- chemical , economics : Antiparkinson Agents, Ergolines, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Ergolines, Levodopa.
- drug therapy : Parkinson Disease.
- economics : Parkinson Disease.
- Age Factors, Cost-Benefit Analysis, Decision Support Techniques, Humans, Middle Aged, Prospective Studies, Questionnaires.
Url:
DOI: 10.1002/mds.20031
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003417
- to stream Istex, to step Curation: 003417
- to stream Istex, to step Checkpoint: 002549
- to stream PubMed, to step Corpus: 003422
- to stream PubMed, to step Curation: 003422
- to stream PubMed, to step Checkpoint: 003338
- to stream Ncbi, to step Merge: 000E62
- to stream Ncbi, to step Curation: 000E62
- to stream Ncbi, to step Checkpoint: 000E62
- to stream Main, to step Merge: 005526
- to stream Main, to step Curation: 003B68
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Re: Cabergoline versus levodopa monotherapy: A decision analysis</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:C64B223EC1E609CA4F0CCE8001B59E268FEB5076</idno>
<date when="2004" year="2004">2004</date>
<idno type="doi">10.1002/mds.20031</idno>
<idno type="url">https://api.istex.fr/document/C64B223EC1E609CA4F0CCE8001B59E268FEB5076/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">003417</idno>
<idno type="wicri:Area/Istex/Curation">003417</idno>
<idno type="wicri:Area/Istex/Checkpoint">002549</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Marras C:re:cabergoline:versus</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15197726</idno>
<idno type="wicri:Area/PubMed/Corpus">003422</idno>
<idno type="wicri:Area/PubMed/Curation">003422</idno>
<idno type="wicri:Area/PubMed/Checkpoint">003338</idno>
<idno type="wicri:Area/Ncbi/Merge">000E62</idno>
<idno type="wicri:Area/Ncbi/Curation">000E62</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E62</idno>
<idno type="wicri:doubleKey">0885-3185:2004:Marras C:re:cabergoline:versus</idno>
<idno type="wicri:Area/Main/Merge">005526</idno>
<idno type="wicri:Area/Main/Curation">003B68</idno>
<idno type="wicri:Area/Main/Exploration">003B68</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Re: Cabergoline versus levodopa monotherapy: A decision analysis</title>
<author><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
<affiliation wicri:level="1"><country wicri:rule="url">Canada</country>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Movement Disorders Centre, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2004-06">2004-06</date>
<biblScope unit="vol">19</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="736">736</biblScope>
<biblScope unit="page" to="736">736</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">C64B223EC1E609CA4F0CCE8001B59E268FEB5076</idno>
<idno type="DOI">10.1002/mds.20031</idno>
<idno type="ArticleID">MDS20031</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Antiparkinson Agents (economics)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cost-Benefit Analysis</term>
<term>Decision Support Techniques</term>
<term>Ergolines (economics)</term>
<term>Ergolines (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (economics)</term>
<term>Levodopa (therapeutic use)</term>
<term>Middle Aged</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (economics)</term>
<term>Prospective Studies</term>
<term>Questionnaires</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Ergolines</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Cost-Benefit Analysis</term>
<term>Decision Support Techniques</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Prospective Studies</term>
<term>Questionnaires</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</noRegion>
<name sortKey="Marras, Connie" sort="Marras, Connie" uniqKey="Marras C" first="Connie" last="Marras">Connie Marras</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B68 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003B68 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:C64B223EC1E609CA4F0CCE8001B59E268FEB5076 |texte= Re: Cabergoline versus levodopa monotherapy: A decision analysis }}
This area was generated with Dilib version V0.6.23. |